Clarivate™

Sample content

Alzheimer's Disease

China In-Depth

Sample content

China In-Depth provides comprehensive market intelligence providing world-class epidemiology, keen insight into the China-specific access & reimbursement environment, current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.

Methodology and scope

Market forecast

- **Forecast**: 10-year, annualized, drug-level sales and patient share of key Alzheimer's Disease therapies through 2033, based on primary and secondary market research to formulate bottom-up assumptions.

- **Epidemiology**: Total, diagnosed, and drug-treated prevalent cases of AD in urban versus rural China, clinically relevant and commercially relevant populations

- **Additional content:** Downloadable Excel files containing detailed forecast assumptions and visual outputs.

Primary market research

- Qualitative and quantitative insights driven by 5 country-specific interviews with thought-leading medical oncologists.

- Supported by survey data collected for this and other Clarivate research.

Geography

China

Coverage

- Key emerging therapies included in the analysis:

| Phase 3/ Registration	Marketed
Octohydroaminoacridine succinate	Donepezil
Donanemab	Rlvastigmine
Remternetug	Memantine
KarXT (Xanomeline, trospium)	Lecanemab

Primary market research methodology

- **Alzheimer's Disease | China In-Depth** is a primary market research study evaluating physician self-reported prescribing and treatment practices for Alzheimer's Disease.

- We interviewed five Alzheimer's Disease specialists in China.
  - The interviews were conducted from November 2024.
  - Each interview was conducted over the phone and lasted approximately 45 minutes.
  - All experts we interviewed have active medical practices with a specific interest in Alzheimer's Disease.

- E-mail invitations were sent to neurologists to participate in a 30-minute online survey.

- 50 neurologists/ dementia specialists completed the survey.

- Surveys were programmed in the local language.

- Fieldwork occurred from November 11 to November 24, 2024.

- To qualify, respondents met the following screening criteria:
  - Specialists in neurology / dementia .
  - Manage at least 12 Alzheimer's disease patients.
  - Prescribe at least acetylcholinesterase inhibitors, NMDA receptor antagonists, and anti-amyloid beta agents outside of clinical trials in 2023.
  - Be in practice for a minimum of 5 years and a maximum of 35 years.
  - Practice in a tier II or III general hospital.
  - Devote more than 50% of their professional time to direct patient care.

- After meeting the screening criteria, respondents were directed to an online survey and were paid an honorarium for their participation.

Clarivate™

Sample content

Question answered

What are the expected sales of key drugs used to treat Alzheimer's Disease in China over the next 10 years?

Sample content

Question answered

What are the expected sales of emerging therapies in development for Alzheimer's Disease in China over the next 10 years?


China In-Depth

Sales of emerging therapies for Alzheimer's Disease in China: 2023-2033

Sample content

Question answered

What is the current treatment paradigm in Alzheimer's Disease? Who are the key influencers and what are the main endpoints explored in clinical trials?

Confirmed diagnosis of Alzheimer's disease

Cognitive symptoms

Affective behavioral symptoms (generally occurring in mild / moderate AD)

Neuropsychiatric symptoms (generally occurring in moderate / severe AD)

Mild AD
AChEIs (donepezil, galantamine, and rivastigmine)

SSRIs (escitalopram, sertraline citalopram, mirtazapine)

Antipsychotics (risperidone, olanzapine, quetiapine)

Mild / moderate AD
AChEIs; occasionally adjunctive memantine; antipsychotics (risperidone, olanzapine, quetiapine); TCMs alone or in combination with AChEIs

Moderate / severe AD
AChEIs; memantine or in combination with AChEIs;
TCMs alone or in combination with AChEIs and/or memantine

## Clarivate™

Sample content

Question answered

What percentage of your Alzheimer's Disease patients had medical financial assistance (MFA) in 2023?

Sample content

Question answered

What clinical unmet needs remain unfulfilled and represent the top opportunities for drug developers?

"Early and accurate diagnosis of AD is essential for starting treatment at the best time, which can improve long-term outcomes. Despite progress in AD research, there are still challenges in identifying and diagnosing AD early, as its initial symptoms are often mistaken for normal aging." — **Chinese neurologist**

Contact our experts today:
healthcare.support@clarivate.com
clarivate.com